Maci is intended to treat symptomatic, full-thickness cartilage defects of the knee.

MACI has not been approved in the US, and is currently under Biologics License Application (BLA) review by the FDA. The MACI implant utilizes autologous chondrocytes which are extracted from a cartilage tissue biopsy of healthy cartilage from the patient’s own knee. To complete the MACI implant the chondrocytes are expanded and seeded on to a bio-resorbable Type I / III collagen membrane at a uniform rate of approximately 1,000,000 cells per square centimeter. During a mini-open technique, damaged and / or diseased cartilage tissue is debrided from the defect area and the MACI implant is cut and shaped to fit and adhered in place using an off-the-shelf sealant.